188 related articles for article (PubMed ID: 38037900)
1. The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
Lasagna A; Mele D; Bergami F; Alaimo D; Dauccia C; Alessio N; Comolli G; Pasi F; Muzzi A; Novelli V; Baldanti F; Pedrazzoli P; Cassaniti I
Hum Vaccin Immunother; 2023 Dec; 19(3):2288282. PubMed ID: 38037900
[TBL] [Abstract][Full Text] [Related]
2. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
J Virol; 2021 May; 95(12):. PubMed ID: 33762414
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
[TBL] [Abstract][Full Text] [Related]
4. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
[TBL] [Abstract][Full Text] [Related]
5. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
[TBL] [Abstract][Full Text] [Related]
6. The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
Dagnew AF; Klein NP; Hervé C; Kalema G; Di Paolo E; Peterson J; Salaun B; Schuind A
J Infect Dis; 2021 Oct; 224(7):1139-1146. PubMed ID: 32103273
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
Hastie A; Catteau G; Enemuo A; Mrkvan T; Salaun B; Volpe S; Smetana J; Rombo L; Schwarz T; Pauksens K; Hervé C; Bastidas A; Schuind A
J Infect Dis; 2021 Dec; 224(12):2025-2034. PubMed ID: 32502272
[TBL] [Abstract][Full Text] [Related]
8. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Boutry C; Hastie A; Diez-Domingo J; Tinoco JC; Yu CJ; Andrews C; Beytout J; Caso C; Cheng HS; Cheong HJ; Choo EJ; Curiac D; Di Paolo E; Dionne M; Eckermann T; Esen M; Ferguson M; Ghesquiere W; Hwang SJ; Avelino-Silva TJ; Kosina P; Liu CS; Markkula J; Moeckesch B; Murta de Oliveira C; Park DW; Pauksens K; Pirrotta P; Plassmann G; Pretswell C; Rombo L; Salaun B; Sanmartin Berglund J; Schenkenberger I; Schwarz T; Shi M; Ukkonen B; Zahaf T; Zerbini C; Schuind A; Cunningham AL;
Clin Infect Dis; 2022 Apr; 74(8):1459-1467. PubMed ID: 34283213
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.
Vink P; Delgado Mingorance I; Maximiano Alonso C; Rubio-Viqueira B; Jung KH; Rodriguez Moreno JF; Grande E; Marrupe Gonzalez D; Lowndes S; Puente J; Kristeleit H; Farrugia D; McNeil SA; Campora L; Di Paolo E; El Idrissi M; Godeaux O; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
Cancer; 2019 Apr; 125(8):1301-1312. PubMed ID: 30707761
[TBL] [Abstract][Full Text] [Related]
10. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
Min JY; Mwakingwe-Omari A; Riley M; Molo LY; Soni J; Girard G; Danier J
J Infect; 2022 Apr; 84(4):490-498. PubMed ID: 34963639
[TBL] [Abstract][Full Text] [Related]
11. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
12. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
[TBL] [Abstract][Full Text] [Related]
13. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial.
Vink P; Ramon Torrell JM; Sanchez Fructuoso A; Kim SJ; Kim SI; Zaltzman J; Ortiz F; Campistol Plana JM; Fernandez Rodriguez AM; Rebollo Rodrigo H; Campins Marti M; Perez R; González Roncero FM; Kumar D; Chiang YJ; Doucette K; Pipeleers L; Agüera Morales ML; Rodriguez-Ferrero ML; Secchi A; McNeil SA; Campora L; Di Paolo E; El Idrissi M; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
Clin Infect Dis; 2020 Jan; 70(2):181-190. PubMed ID: 30843046
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
Stefanizzi P; Moscara L; Palmieri C; Martinelli A; Di Lorenzo A; Venerito V; Germinario CA; Tafuri S
Vaccine; 2024 Apr; 42(12):2966-2974. PubMed ID: 38582693
[TBL] [Abstract][Full Text] [Related]
16. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
[TBL] [Abstract][Full Text] [Related]
17. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
[TBL] [Abstract][Full Text] [Related]
18. Herpes Virus Infections in Kidney Transplant Patients (HINT) - a prospective observational cohort study.
Hamm SR; Saini SK; Hald A; Vaaben AV; Pedersen NW; Suarez-Zdunek MA; Harboe ZB; Bruunsgaard H; Johansen IS; Larsen CS; Bistrup C; Birn H; Sørensen SS; Hadrup SR; Nielsen SD
BMC Infect Dis; 2023 Oct; 23(1):687. PubMed ID: 37845608
[TBL] [Abstract][Full Text] [Related]
19. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients.
Racine É; Gilca V; Amini R; Tunis M; Ismail S; Sauvageau C
Vaccine; 2020 Sep; 38(40):6205-6214. PubMed ID: 32788132
[TBL] [Abstract][Full Text] [Related]
20. Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines.
Weinberg A; Scott Schmid D; Leung J; Johnson MJ; Miao C; Levin MJ
J Infect Dis; 2023 Nov; 228(10):1367-1374. PubMed ID: 37141390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
